Phase Ib/II Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation
Status:
Not yet recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
Evaluate the safety and tolerability, drug levels, and clinical activity of JAB-21822 in
patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors
with KRAS p.G12C mutation and a serine/threonine kinase 11 (STK11) co-mutation.